James I.  Healy net worth and biography

James Healy Biography and Net Worth

Director of Coherus BioSciences

James I. Healy, M.D., Ph.D. has been a member of our Board of Directors since February 2014.

Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Ascendis Pharma, Bolt Biotherapeutics, Natera, Karuna Therapeutics, NuCana plc, and Y-mAbs Therapeutics, and is a board observer at Visen. Previously, he served as a board member of InterMune, Inc., Amarin Corp., Auris Medical, Hyperion Therapeutics, Inc., Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV and several private companies.

Dr. Healy holds an M.D. and a Ph.D. in Immunology from the Stanford University School of Medicine, a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley.

What is James I. Healy's net worth?

The estimated net worth of James I. Healy is at least $100,944.04 as of December 13th, 2023. Dr. Healy owns 42,236 shares of Coherus BioSciences stock worth more than $100,944 as of March 29th. This net worth estimate does not reflect any other investments that Dr. Healy may own. Learn More about James I. Healy's net worth.

How do I contact James I. Healy?

The corporate mailing address for Dr. Healy and other Coherus BioSciences executives is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. Coherus BioSciences can also be reached via phone at (650) 649-3530 and via email at [email protected]. Learn More on James I. Healy's contact information.

Has James I. Healy been buying or selling shares of Coherus BioSciences?

James I. Healy has not been actively trading shares of Coherus BioSciences over the course of the past ninety days. Most recently, James Healy sold 286,076 shares of the business's stock in a transaction on Wednesday, September 29th. The shares were sold at an average price of $16.12, for a transaction totalling $4,611,545.12. Learn More on James I. Healy's trading history.

Who are Coherus BioSciences' active insiders?

Coherus BioSciences' insider roster includes James Healy (Director), Dennis Lanfear (CEO), McDavid Stilwell (CFO), and Vladimir Vexler (Insider). Learn More on Coherus BioSciences' active insiders.

Are insiders buying or selling shares of Coherus BioSciences?

In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 223,100 shares worth more than $450,662.00. The most recent insider tranaction occured on November, 22nd when CEO Dennis M Lanfear sold 223,100 shares worth more than $450,662.00. Insiders at Coherus BioSciences own 11.0% of the company. Learn More about insider trades at Coherus BioSciences.

Information on this page was last updated on 11/22/2023.

James I. Healy Insider Trading History at Coherus BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2021Sell286,076$16.12$4,611,545.12View SEC Filing Icon  
9/27/2021Sell100,150$18.06$1,808,709.00View SEC Filing Icon  
7/2/2019Sell360,000$22.30$8,028,000.0092View SEC Filing Icon  
6/28/2019Sell200,000$22.05$4,410,000.0092View SEC Filing Icon  
6/20/2019Sell317,130$21.37$6,777,068.1092View SEC Filing Icon  
5/22/2019Sell257,870$20.69$5,335,330.3092View SEC Filing Icon  
8/29/2018Sell25,000$20.50$512,500.00View SEC Filing Icon  
See Full Table

James I. Healy Buying and Selling Activity at Coherus BioSciences

This chart shows James Healy's buying and selling at Coherus BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Coherus BioSciences Company Overview

Coherus BioSciences logo
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $2.39
Low: $2.36
High: $2.51

50 Day Range

MA: $2.39
Low: $2.02
High: $2.85

2 Week Range

Now: $2.39
Low: $1.43
High: $8.65

Volume

2,093,169 shs

Average Volume

4,356,623 shs

Market Capitalization

$269.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54